NDLI: Colchicine Drug-to-drug Interactions

Please wait, while we are loading the content...

Colchicine Drug-to-drug Interactions

Content Provider	The Lens
Abstract	The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.
Related Links	https://www.lens.org/lens/patent/129-146-615-058-701/frontpage
Language	English
Publisher Date	2020-02-06
Access Restriction	Open
Content Type	Text
Resource Type	Patent
Jurisdiction	United States of America
Date Applied	2019-08-19
Applicant	Rxomeg Therapeutics Llc
Application No.	201916544607
Claim	A method of treating a colchicine sensitive disorder, comprising orally co-administering a liquid colchicine solution and a P-gp inhibitor to a human subject having a colchicine sensitive disorder in an effective amount to treat the disorder, wherein there is no significant effect on colchicine blood levels when the liquid colchicine solution is taken in conjunction with carvedilol phosphate, and wherein the dose of colchicine is 0.5-1.2 mg/dose/day. The method of claim 1 , wherein the P-gp inhibitor is carvedilol phosphate. 3 - 5 . (canceled) A method of treating a colchicine sensitive disorder, comprising orally co-administering a liquid colchicine solution and a CYP3A4 inhibitor to a human subject having a colchicine sensitive disorder in an effective amount to treat the disorder, wherein there is a 2-6 fold increase in colchicine blood levels when posaconazole is co-administered with the liquid colchicine solution. The method of claim 6 , wherein the CYP3A4 inhibitor is a strong CYP3A4 inhibitor. The method of claim 6 , wherein strong CYP3A4 inhibitor is posaconazole. The method of claim 8 , wherein the dose of posaconazole is 300-600 mg/dose/day. The method of claim 8 , wherein the dose of liquid colchicine solution is reduced to 2.5 mL/day or lower when coadministered with posaconazole. (canceled) A method of treating a colchicine sensitive disorder, comprising orally co-administering a liquid colchicine solution and a weak CYP3A4 inhibitor to a human subject having a colchicine sensitive disorder in an effective amount to treat the disorder, wherein there is no significant effect on colchicine blood levels. The method of claim 12 , wherein the weak CYP3A4 inhibitor is amlodipine besylate. The method of claim 13 , wherein the dose of amlodipine besylate is 5-10 mg/dose/day. A method of treating a colchicine sensitive disorder, comprising orally co-administering a liquid colchicine solution and a moderate CYP3A4 inhibitor, wherein there is no significant effect on colchicine blood levels. The method of claim 16 , wherein the moderate CYP3A4 inhibitor is ciprofloxacin hydrochloride. The method of claim 17 , wherein the dose of ciprofloxacin hydrochloride is 20-750 mg/dose/day. The method of claim 6 , wherein the dose of colchicine is 0.5-1.2 mg/dose/day. A method of treating a colchicine sensitive disorder, comprising orally administering a liquid colchicine solution to a human subject having a colchicine sensitive disorder in an effective amount to treat the disorder, wherein the liquid colchicine solution has less than 0.5% of degradants. 23 - 24 . (canceled) The method of claim 22 , wherein the colchicine sensitive disorder is selected from gout, prophylactic treatment of gout, familial Mediterranean fever (FMF), prophylactic treatment of FMF, pericarditis, prophylactic treatment of pericarditis, Behçet's disease, atrial fibrillation, prophylactic treatment of atrial fibrillation, amyloidosis, calcium pyrophosphate deposition disease (pseudogout), cirrhosis of the liver, sarcoid arthritis, inflammatory diseases, and disc diseases and related spinal disorders. The method of claim 22 , further comprising monitoring the subject for colchicine adverse events. The method of claim 22 , wherein the degradants comprise β-lumicolchicine, γ-lumicolchicine, and/or colchiceine.
CPC Classification	Preparations For Medical; Dental Or Toiletry Purposes Specific Therapeutic Activity Of Chemical Compounds Or Medicinal Preparations
Extended Family	154-842-463-048-680 129-146-615-058-701 094-883-665-285-47X 131-984-434-025-673 023-626-240-792-81X 053-164-849-065-465 133-243-982-984-079 067-172-768-956-07X 186-143-800-691-692
Patent ID	20200038322
Inventor/Author	Muni Indu Vishnupad Naomi
IPC	A61K9/08 A61K9/00 A61K31/165 A61K31/403 A61K31/4422 A61K31/4709 A61K31/496 A61K47/02 A61K47/12 A61K47/36 A61P19/02 A61P29/00 A61P31/00
Status	Active
Owner	Rxomeg Therapeutics Llc
Simple Family	154-842-463-048-680 129-146-615-058-701 094-883-665-285-47X 131-984-434-025-673 023-626-240-792-81X 053-164-849-065-465 133-243-982-984-079 067-172-768-956-07X 186-143-800-691-692
CPC (with Group)	A61K31/403 A61K9/0053 A61K9/08 A61K31/165 A61K31/496 A61K2300/00 A61P1/02 A61P1/16 A61P9/06 A61P19/02 A61P19/06 A61P29/00 A61K9/0095 A61K31/4422 A61K31/4709 A61K47/02 A61K47/10 A61K47/12 A61K47/26 A61K47/36 A61P31/00
Issuing Authority	United States Patent and Trademark Office (USPTO)
Kind	Patent Application Publication

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Colchicine Drug-to-drug Interactions

Modulation of Drug-drug Interactions of Vadadustat

Modulation of Drug-drug Interactions of Vadadustat

Modulation of Drug-drug Interactions of Vadadustat

Method of Administering Upadacitinib to Avoid Adverse Drug Interactions and Effects

Method of Administering Upadacitinib to Avoid Adverse Drug Interactions and Effects

Use of Colchicine to Inhibit Tumor Growth and Metastases

Use of Colchicine to Inhibit Tumor Growth and Metastases

Methods for Preventing Toxic Drug-drug Interactions in Combination Therapies Comprising Anti-erbb3 Agents.

Colchicine Drug-to-drug Interactions

Similar Documents

Colchicine Drug-to-drug Interactions

Modulation of Drug-drug Interactions of Vadadustat

Modulation of Drug-drug Interactions of Vadadustat

Modulation of Drug-drug Interactions of Vadadustat

Method of Administering Upadacitinib to Avoid Adverse Drug Interactions and Effects

Method of Administering Upadacitinib to Avoid Adverse Drug Interactions and Effects

Use of Colchicine to Inhibit Tumor Growth and Metastases

Use of Colchicine to Inhibit Tumor Growth and Metastases

Methods for Preventing Toxic Drug-drug Interactions in Combination Therapies Comprising Anti-erbb3 Agents.

Colchicine Drug-to-drug Interactions